Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-08-07
2007-08-07
Davis, Zinna N. (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S252140, C514S256000, C514S302000, C514S307000, C514S379000, C514S443000, C546S115000, C546S139000, C548S241000, C549S049000, C544S106000, C544S242000, C544S359000
Reexamination Certificate
active
10844245
ABSTRACT:
The compounds are of the class of benzisoxazolyl-, pyridoisoxazolyl- and benzthienyl-phenoxy derivatives, useful as D4antagonists. Said compounds are useful for the treatment of medical conditions mediated by inhibition of D4receptor. These conditions comprise, for example, Attention Deficit Hyperactivity Disorder, Obsessive-Compulsive Disorder, Psychoses, Substance Abuse, Substance Dependence, Parkinson's Disease, Parkinsonism, Tardive Diskinesia, Gilles de la Tourette Syndrome, Conduct Disorder, and Oppositional Defiant Disorder. A further aspect of the invention is to provide a pharmaceutical composition, intermediates, and a method of making said class of compounds.
REFERENCES:
patent: 4075227 (1978-02-01), Jones et al.
patent: 4085114 (1978-04-01), Adachi et al.
patent: 4355037 (1982-10-01), Strupczewski et al.
patent: 4408053 (1983-10-01), Strupczewski et al.
patent: 4408054 (1983-10-01), Strupczewski et al.
patent: 4427691 (1984-01-01), Shutske et al.
patent: 4452804 (1984-06-01), Shutske et al.
patent: 4469869 (1984-09-01), Strupczewski et al.
patent: 4504669 (1985-03-01), Shutske et al.
patent: 4528376 (1985-07-01), Strupczewski et al.
patent: 4644064 (1987-02-01), Shutske et al.
patent: 4728651 (1988-03-01), Ong et al.
patent: 4769472 (1988-09-01), Ong et al.
patent: 5114936 (1992-05-01), Wettlaufer et al.
patent: 5143923 (1992-09-01), Hrib et al.
patent: 5177088 (1993-01-01), Effland et al.
patent: 5180834 (1993-01-01), Wettlaufer et al.
patent: 5225412 (1993-07-01), Hrib et al.
patent: 5225414 (1993-07-01), Henning et al.
patent: 5254595 (1993-10-01), Guzzi et al.
patent: 5256672 (1993-10-01), Wettlaufer et al.
patent: 5321037 (1994-06-01), Nagano et al.
patent: 5328920 (1994-07-01), Effland et al.
patent: 5340833 (1994-08-01), Bridges et al.
patent: 5576319 (1996-11-01), Baker et al.
patent: 5593994 (1997-01-01), Batt et al.
patent: 5696113 (1997-12-01), Palermo et al.
patent: 5780474 (1998-07-01), Peglion et al.
patent: 5843940 (1998-12-01), Cullinan et al.
patent: 5852022 (1998-12-01), Palermo et al.
patent: 5856503 (1999-01-01), Aebi et al.
patent: 5932586 (1999-08-01), Batt et al.
patent: 5965554 (1999-10-01), Palermo et al.
patent: 6008348 (1999-12-01), Palermo et al.
patent: 6022880 (2000-02-01), Effland et al.
patent: 6103724 (2000-08-01), Laszlovszky et al.
patent: 6121293 (2000-09-01), Cullinan et al.
patent: 0058977 (1982-09-01), None
patent: 0221414 (1987-05-01), None
patent: 0729955 (1996-09-01), None
patent: 1269776 (1972-04-01), None
patent: 10095770 (1998-04-01), None
patent: WO 92/08718 (1992-05-01), None
patent: WO 97/23482 (1997-07-01), None
patent: WO 97/28115 (1997-08-01), None
patent: WO 97/40027 (1997-10-01), None
patent: WO 99/40067 (1999-08-01), None
patent: WO 01/19833 (2001-03-01), None
Asghari, V., et. al., Dopamine D4 Receptor Repeat: Analysis of Different Native and Mutant Forms of the Human and Rat Genes, Molecular Pharmacology vol. 46, pp. 364-373 (1994).
Bassitt, D.P., et. al., Clozapine Efficacy in Tardive Dyskinesia in Schizophrenic Patients, European Archives of Pyschiatry and Clinical Neuroscience vol. 248, pp. 209-211 (1998).
Benjamin, J., et. al., Population and Familial Association between the D4 Dopamine Receptor gene and Measures of Novelty Seeking, Nature Genetics vol. 12, pp. 81-84 (1996).
Bryce, M., et. al., Synthesis and Cyclic Voltammetric Behaviour of Some 3-Substituted Thiophenes and Pyrroles: Precursors for the Prepration of Conducting Polymers, Synthetic Metal, vol. 26, (1988) pp. 153-168.
Corbett, R., et. al., Iloperidone: Preclinical Profile and Early Clinical Evaluation, CNS Drug Review vol. 3, No. 2, pp. 120-147 (1997).
Crenshaw, R.R., et. al., Potential Antifertility Agents, 1. Substituted Diarl Derivatives of Benzo[b]thiophenes, Benzo[b]furans, 1H-2-Benzothiapyrans, and 2H-1-Benzothiapyrans1, Journal of Medicinal Chemistry, vol. 14, No. 12, (1971) pp. 1185-1190.
Cruz, C., et. al., Increased Prevalence of the Seven-Repeat Variant of the Dopamine D4 Receptor Gene in Patients with Obsessive-Compulsive Disorder with Tics, Neuroscience Letters vol. 231, pp. 1-4, (1997).
Ebstein, R.E., et. al., Dopamine D4 Receptor (D4DR) exon III Polymorphism Associated with the Human Personality Trait of Novelty Seeking, Nature Genetics vol. 12, (1996) pp. 78-80.
Elworthy, T. R., et. al., N-Arylpiperazinyl-N-Propylamino Derivatives of Heteroaryl Amides as Functional Uroselective a1-Adrenoceptor Antagonists, Indian Journal of Chemistry—part B Organic Including Medicinal vol. 40, pp. 2674-2687, (1997).
Erenberg, G., et. al. , Giles De La Tourette's Syndrome: Effects of Stimulant Drugs, Neurology vol. 35, No. 35, pp. 1346-1348, (1985).
Factor, S.A., et. al., The Emerging Role of Clozapine in the Treatment od Movement Disorders, Movement Disorders vol. 12, No. 4 (1997) pp. 483-496.
Feldpausch, D.L., et. al., The Role of Dopamine D4 Receptor in the Induction of Behavioral Sensitization to Amphetamine and Accompanying Biochemical and Molecular Adaptations, Journal of Pharmacology and Experimental Therapeutics vol. 266, pp. 497-508 (1998).
Friedman, J.H., et. al., Substituting Clozapine for Olanzapine in Psychiatrically Stable Parkinson's Disease Patients: Results of an Open Label for Pilot Study, Clinical Neuropharmacology, vol. 21, No. 5 pp. 285-288 (1998).
Grice, D.E., et. al., Linkage Disequillibrium between an Allele at the Dopamine D4 Receptor Locus and Tourette Syndrome, by the Transmission-Disequillibrium Test, American Journal of Human Genetics vol. 59, pp. 644-652 (1996).
Helsley, G.C., et. al., Piperidyalkylindoles. 1. Hypotensive Activity of 3-[2-(Phenoxypiperidyl)ethyl]indoles, Journal of Medicinal Chemistry, (1978), vol. 21, No. 3 pp. 309-312.
Lahoste, G., et. al., Dopamine D4 Receptor Gene Polymorphism is Associated with Attention Deficit Hyperactivity Disorder, Molecular Psychiatry vol. 1, pp. 121-124 (1996).
Lahti, R.A., et. al., Direct Determination of Dopamine D4 Receptors in Normal and Schizophrenic Postmortem Brain Tissue: A[3H]NGD-94-1 Study, Molecular Psychiatry vol. 3, pp. 528-533 (1998).
Magdo, I., et. al., 3D quantitative structure-activity relationship (CoMFA) study of heterocyclic arylpiperazine derivatives with 5-HT1A activity, Database Chemabs ′Online! Chemical Abstracts Service, Columbus, Ohio, US.
Ricketts, H., et al., Association of Long Variants of the Dopamine D4 Receptor Exon 3 Repeat Polymorphism with Parkinson's Disease, Clinical Genetics vol. 54, pp. 33-38 (1998).
Rubinstein, M., et. al., Mice Lacking Dopamine D4 Receptors are Supersitive to Ethanol, Cocaine, and Methamphetamine, Cell, vol. 90, pp. 991-1001 (1997).
Sall, D., et. al., Dibasic Benzo[b]thiophene Derivatives as a Novel Class of Active Site-Directed Thrombin Inhibitors. 1. Determination of the Serine Protease Selectivity, Structure—Activity Relationships, and Binding Orientation, Journal of Medicinal Chemistry vol. 40, No. 22, (1997) pp. 3489-3493.
Schoder, J., et. al. , D2 Dopamine Receptor Up-Regulation, Treatment Response, Neurological Soft Signs, and Extrapyramidal Side Effects in Schizophrenia: A Follow-Up Study with 123I-Iodobenzamide Single Photon Emission Compouted Tomography in the Drug Naive State and after Neuroleptic Treatment, Society of Biological Psychiatry vol. 43, pp. 660-665, (1998).
Seeman, P., et. al., Atypical Neuroleptics Have Low Affinity for Dopamine D2 Receptors or Are Selectivefor D4 Receptors, Neuropoychoppharmacology vol. 16, Iss. 2, pp. 92-135 (1997).
Seeman, P., et. al., Schizophrenia: Eleveation of dopamine D4-like sites, using [3H] Nemonapride and 125I Epidepride , European Journal of Pharmacology vol. 286 (1995) R3-R5.
Shields, P.G., et. al., Dopamine D4 Receptors and the Risk of Cigarette Smoke in African-Americans and Caucasions1, Cancer Epidermiology, Biomarkers & Prevention vol. 7, pp. 453-458 (1998).
Van Tol, H.M., et. al., Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine, Letters to Nature, vol. 350, 1991, pp. 610-614.
Van Tol, H.M., et. al., The Dopamine D4 Receptor: A Novel Site for Antipsychotic Action , Clinical N
Freed Brian S.
Hanna Reda G.
Hendrix James A.
Hrib Nicholas J.
Jurcak John G.
Aventis Pharmaceuticals Inc.
Davis Zinna N.
Kurys Barbara E.
LandOfFree
Benzisoxazolyl-, pyridoisoxazolyl-and benzthienyl-phenoxy... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Benzisoxazolyl-, pyridoisoxazolyl-and benzthienyl-phenoxy..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Benzisoxazolyl-, pyridoisoxazolyl-and benzthienyl-phenoxy... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3899344